At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Biomarker Guided Therapies in Stage A/B Heart Failure
In Brief
A Phase 2 clinical trial evaluating Carvedilol, Spironolactone, and 1 other intervention for Hypertension and 2 related conditions. Completed, enrolled 58 participants across 1 site.
Detailed Summary
Despite advances in cardiovascular care, the occurrence of heart failure (HF) is steadily increasing. The increase in HF rates poses enormous challenges, as once an individual becomes symptomatic or requires hospitalization with HF, the prognosis remains poor. Therefore, prevention of HF is essential. HF prevention is a critical issue as HF risk factors that include common medical conditions such as hypertension and diabetes are also increasing. However, not everyone with these risk factors develops HF. Using novel blood tests, the investigators propose to identify and treat subjects at higher HF risk to see if the investigators can stabilize or improve ultrasound measures known to be associated with HF risk. This study will enroll only Veterans.
Study Details
Timeline
Interventions
Carvedilol is a non selective beta blocker
Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
standard care as per primary care provider